Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM
- 278 Downloads
The social media platform Twitter has provided the hematology/oncology community with unprecedented, novel methods of interpersonal communication and increased ability for the dissemination of important updates in a rapidly moving field. The advent, and subsequent success, of disease-specific Twitter communities have further enabled interested healthcare stakeholders to become quickly organized around a unique set of rare medical conditions, such as hematologic malignancies, that, historically, generally lack large amounts of reliable online information. One example is the Twitter community #MPNSM (myeloproliferative neoplasms on social media), which was started approximately one and half years ago and has served as a recognized venue for discussion among many members of the MPN community, including patients, researchers, providers, and advocacy organizations. This article will focus on understanding the impact of the founding of this community via the analysis of advanced Twitter metrics of user experience, from the first year of use for this novel healthcare hashtag.
KeywordsSocial media Twitter Myeloproliferative neoplasm Disease-specific hashtag Myelofibrosis Polycythemia vera
This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672. The authors thank Dr Matthew Katz and the creators of the Cancer Ontology Tag (CTO) Program for their example and inspiration, and the founders and members of Symplur, and the Healthcare Hashtags Project for their continued analysis and support.
Compliance With Ethical Standards
Conflict of Interest
Naveen Pemmaraju reports Honorarium/Consulting and/or Research and Clinical trial support: Novartis, LFB, Incyte, Stemline, Cellectis.
Vikas Gupta received research grants from Novartis, Incyte, Gilead, and Promedior through his institution; served on scientific advisory board of Novartis, Incyte and received honorarium from Novartis/Incyte.
Audun Utengen is the Co-founder of Symplur.
Michael A. Thompson has been on Advisory Boards for: AIM Specialty Health, BMS, Celgene, Doximity, MDRing, Takeda, VIA Oncology, and Xconomy. Dr. Thompson owns stock in Doximity.
Ruben Mesa is the Editor-in-Chief of Current Hematologic Malignancy Reports.
Jean-Jacques Kiladjian reports grants from Novartis and AOP Orphan and personal fees from Novartis, Incyte, AOP Orphan, and Shire.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.Abernethy AP, Grubbs SS. Managing cumulative expectations in oncology: challenges and potential solutions. Am Soc Clin Oncol Educ Book. 2014;e140-144. doi: 10.14694/EdBook_AM.2014.34.e140
- 3.Thompson MA. Using social media to learn and communicate: it is not about the tweet. Am Soc Clin Oncol Educ Book. 2015;206–211.Google Scholar
- 4.Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urol Oncol. 2016.Google Scholar
- 14.Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (mpn)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015.Google Scholar
- 15.Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:6520.Google Scholar
- 16.Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer Communication in the Social Media Age. JAMA Oncol. 2016;2(6):822-3.Google Scholar
- 17.Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (aya) patient with cancer. Curr Hematol Malig Rep. 2016.Google Scholar
- 18.Thompson MA. Social media in clinical trials. Am Soc Clin Oncol Educ Book. 2014; e101-105. doi: 10.14694/EdBook_AM.2014.34.e101